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http://dx.doi.org/10.1016/j.asjsur.20Summary Background/Objective: Chronic anal fissure is a painful condition that is associ-
ated with an increase in internal anal sphincter pressure. The main aim of this study is to eval-
uate the efficacy and adverse effects of topical isosorbide 5 mononitrate and topical diltiazem,
when administered either as single agents or in combination, in the treatment of anal fissure.
Methods: Patientswith chronic anal fissurewereenrolled in the study.Theywere randomized into
three groups: Group A (0.2% isosorbide 5 mononitrate users), Group B (2% diltiazem users), and
Group C (2%diltiazem þ 0.2% isosorbide 5 mononitrate users). Pain was evaluated using a visual
analog scale (VAS). Level of strain during defecation was graded on a 4-point scale.
Results: A total of 55 patients were enrolled in the study. The average ages of patients in Groups
A, B, and C were 37.94  16.19, 42.83  13.21, 40  13.58 years, respectively. After treatment,
pain completely abated in 55.6% of patients in Group A, 27.8% (n Z 5) in Group B, and 42.1%
(nZ 8) in Group C. The decreases in average VAS values prior to and after treatment in Groups
A, B, and C were statistically significant (p values 0.0001, 0.001, and 0.0001, respectively).
Average strain scores prior to and after treatment were 2.11/0.72 for Group A, 2.17/0.94 for
Group B, and 1.95/0.47 for Group C. Strain during defecation prior to and after treatment in
Groups A, B, and C was statistically significant (p values 0.001, 0.001, and 0.003, respectively).t of Gastroenterology, Osmaniye Public Hospital, Raufbey Mahallesi, Atatu¨rk Caddesi Number 432
iye, Turkey.
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166 H. Bulus et al.Conclusion: Topical diltiazem and a combination of nitrate and diltiazem can be used in the
treatment of anal fissure. However, the agents are not significantly superior each other.
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reserved.1. Introduction during defecation), whether or not fissure improved afterChronic anal fissure is a painful condition that is associated
with an increase in internal anal sphincter pressure. The
aim of fissure treatment is to increase mucosal blood flow
by reducing or eliminating the spasm in the anal sphincter
and improve the fissure symptoms.1,2 Anal fissure can be
healed by a wide range of treatments, including medical
(topical or oral) and surgical treatments. These treatment
methods increase local blood supply and help heal the
fissure by reducing hypertony. In the treatment of fissure,
surgical or chemical sphincterotomy is performed.3,4 Many
studies have proved the efficacy of various chemical agents
in reducing anal sphincter pressure, and many topical and
systemic agents have been used for this purpose.2e4 In
many studies, nitrates and calcium channel blockers have
been used in the treatment of anal fissure. Some studies
have shown that increased nitrate concentrations result in
increased improvement ratios. Some studies have shown
that headache, which is the most important adverse effect
of nitrates, increases with an increase in the dose. The
success ratios of topical calcium blockers have been found
to be equivalent to those of nitrates.5 The goal of this study
is to evaluate the efficacy and adverse effects of topical
isosorbide 5 mononitrate and topical diltiazem when
administered as single agents or in combination.2. Material and methods
Patients with chronic anal fissure presenting to the General
Surgery Clinic of Kec¸io¨ren Training and Research Hospital
between December 2010 and April 2011 were enrolled in the
study. Informed consent was obtained from all patients.
Rectoscopic examination was performed on all patients to
exclude other pathologies. The inclusion criteria for this
study were as follows: (1) patients had been experiencing
chronic anal fissure symptoms formore than2months; (2) the
classic triad of hypertrophied anal papilla, sentinel skin tag,
andexposed internal sphinctermuscle fiberswas present; (3)
prior to the use of topical nitroglycerin (NTG) and diltiazem,
all patientswere treatedwith a conservative regimen of bulk
agents andwarm sitz baths for 6 weeks. Exclusion criteria for
the study included complicated Grade IIIeIV hemorrhoidal
disease, pregnancy, puerperal period, systemic diseases
interfering with wound healing (chronic obstructive lung
disease (COPD), diabetes mellitus (DM), congestive cardiac
failure (CCF), collagen tissue disease, etc.), and inflamma-
tory intestinal disease.
Patients were randomized into three groups: Group A
(n Z 18; 0.2% isosorbide 5 mononitrate users), Group B
(n Z 18; 2% diltiazem users), and Group C (n Z 19; 2%
diltiazem þ 0.1% isosorbide 5 mononitrate users). Ages,
genders, physical examination and rectoscopy results,
symptoms prior to and after treatment (pain, strainingtreatment, and complications caused by treatment were
recorded. Patients in Group A were asked to apply 0.2%
isosorbide 5 mononitrate (a pea- or chickpea-sized amount;
approximately 1 g) twice daily to the anodermal area for a
period of 8 weeks. Patients in Group B were asked to apply a
2% diltiazem pomade and those in Group C to apply a
pomade containing 2% diltiazem and 0.1% isosorbide 5
mononitrate to the anus, twice daily for 8 weeks in both
cases. Patients in each group were advised to consume fiber-
rich and high-water-content diet. No other medicines were
given to the patients. All patients were contacted 1 week
after the initiation of treatment for assessment of compli-
cations (headache, perianal irritation, hypotension, incon-
tinence, pain, bleeding, etc.). At the end of the 8-week
treatment, patients were evaluated with respect to physical
examination results, symptoms, and complications. Pain
was evaluated using a visual analog scale (VAS). Patients
were asked to score the pain prior to and after 8 weeks of
treatment. In a VAS a 10-cm-long straight line, called a visual
evaluation scale, is used for ranking pain intensity. On this
straight line, “0” represents absence of pain and “10” rep-
resents unbearable pain. Changes in pain intensities in the
patients of three groups during the period between prior to
and after treatment were recorded on a VAS and compared.
Level of strain during defecation was graded on a four-point
scale: serious strain was scored as 3, moderate strain as 2,
mild strain as 1, and defecation without strain as 0. Patients
of all the groups were asked to specify their level of strain
during defecation prior to and after treatment.
Statistical evaluation was performed by Biostatistics
Department using SPSS 18 for Windows software. Unidirec-
tional analysis of variance (ANOVA) and chi-square (c2) test
were used for evaluating the age and gender distributions,
respectively. As the number of study participants was less,
the Fisher exact chi-square test was used for the evaluation
of improvement in fissure and its complications. To evaluate
the difference in patient’s pain and strain scores prior to and
after treatment between the groups, nonparametric Krus-
kaleWallis variance analysis was used. Wilcoxon test was
used for the evaluation of the differences in pain and strain
scores prior to and after treatment within each group. A p
value of <0.05 was considered statistically significant.
3. Results
At the beginning of the study, 60 patients with chronic anal
fissure were enrolled. However, during the study one pa-
tient discontinued treatment and four patients failed to
turn up for checkups, and they were excluded from the
study. The study continued with a total of 55 patients (18
patients each in Groups A and B, and 19 patients in Group
C). The average ages of patients in Groups A, B, and C were
37.94  16.19, 42.83  13.21, and 40  13.58 years,
respectively. There were no statistically significant
Table 1 Demographic data and pain reduction ratios of patients.
Group No. patients Mean age (y) ATD AKD AHD
A 18 37.94  16.19 55.6% (10) 22.2% (4) 22.2% (4)
B 18 42.83  13.21 27.8% (5) 44.4% (8) 27.8% (5)
C 19 40  13.58 42.1% (8) 36.8% (7) 21.1% (4)
p 0.865 0.0858
AHD Z less than 50% reduction in pain or no difference; AKD Z More than 50% reduction in pain; ATD Z disappearance of pain.
Treatment of chronic anal fissure 167differences between the groups with respect to age and
gender (p Z 0.865 and p Z 0.858, respectively) (Table 1).
Pain abated completely in 55.6% of patients (n Z 10) in
Group A, 27.8% (n Z 5) in Group B, and 42.1% (n Z 8) in
Group C; greater than 50% reduction in pain was observed in
22.2% of patients (nZ 4) in Group A, 44.4% (nZ 8) in Group
B, and 36.8% (nZ 7) in Group C; and no change or less than
50% reduction in pain was observed in 22.2% of patients
(n Z 4) in Group A, 27.8% (n Z 5) in Group B, and 21.1%
(n Z 4) in Group C after treatment (Table 1). The average
pain scores prior to/after treatment were found to be 6.5/
1.67 in Group A, 8.11/3.22 in Group B, and 7/1.89 in Group
C. Accordingly, the reduction of the VAS average value
within each group in the period between prior to and after
treatment was found to be statistically significant. The p
values in Groups A, B, and C were found to be 0.0001,
0.001, and 0.0001, respectively. When the change in the
VAS values prior to and after treatment for the three groups
were compared, no statistically significant differences
were found between them (p Z 0.957) (Tables 2 and 3).
Average strain scores prior to and after treatment were
evaluated to be 2.11/0.72 for Group A, 2.17/0.94 for Group
B, and 1.95/0.47 for Group C. For each group, the reduction
in strain score during defecation in the period between
prior to and after treatment was found to be statistically
significant. The p values for Groups A, B, and C were 0.001,
0.001, and 0.003, respectively. The differences in strain
scores during defecation prior to and after treatment for
the groups, were not statistically significant (p Z 0.888)
(Tables 2 and 3).
No significant difference was found between the groups
with respect to the improvement in physical examination
results (p Z 0.990). The improvement ratios for all three
groups were found to be similar. In 77.8% of the patients
(nZ 14) in Group A, 72.2% (nZ 13) in Group B , and 73.7%
(nZ 14) in Group C, fissure was observed to have improved
(Fig. 1). The most common complications encountered in all
three groups were headache and itchiness (Fig. 2); headache
was observed in eight patients (4 inGroupA, 1 inGroupB, andTable 2 Differences in VAS scores and DSSs within a group
prior to and after treatment.
Group BT VAS AT VAS p BT DSS AT DSS p
A 6.5 1.67 0.0001 2.11 0.72 0.001
B 8.11 3.22 0.001 2.17 0.94 0.001
C 7 1.89 0.0001 1.95 0.47 0.003
AT Z after treatment; BT Z before treatment;
DSS Z defecation strain score; VAS Z visual analog scale.3 in Group C) and itchiness in nine patients (2 in Group A, 2 in
Group B, and 5 in Group). For headache and itchiness, there
were no statistically significant differences between the
groups (p Z 0.359 and p Z 0.350, respectively). Perianal
dermatitis was observed in one patient in Group B and
erectile dysfunction in one patient in Group C. Gas or stool
incontinence was not seen in any of the patients (Table 2).
4. Discussion
In this study, we determined that topical nitrate and topical
diltiazem separately, and their combination all are effica-
cious in the treatment of chronic anal fissure. Additionally,
when we compared the three groups that used these three
treatments, none of them were found to be superior to
others with respect to VAS score, strain during defecation
score, and improvement of fissure. We observed that the
most common adverse events in each of the three groups
were headache and itchiness.
Anal fissure develops in approximately 10e15% of the
patients presenting with proctologic discomfort. The most
common symptoms are pain and rectal bleeding.2 It is
known that anal sphincter spasm and the ischemia devel-
oping after spasm lead to chronic anal spasm. The aim of
chronic anal fissure treatment is to remove ischemia by
reducing spasm. Various surgical and medical treatments
have been tried for healing anal fissure.1,4,5 Chemical
sphincterotomy have been suggested as an alternative to
surgery to avoid possible complications of surgical treat-
ment. Among these, nitrates, calcium channel blockers,
and botulinum toxin are the most studied and used
agents.2,3,5
Nitroglycerin contributes to anodermal blood flow by
reducing anal sphincter pressure. Transdermal absorption
of nitrates is through passive diffusion, and varies
depending on people and the site of administration. Hence,
it is difficult to standardize the administration of this
medicine.3 In a prospective study by Lund et al6 where itTable 3 Differences in VAS scores and DSSs between
groups prior to and after treatment.
Group VAS BATD DSS BATD
A 4.83  2.95 1.38  1.14
B 4.88  3.19 1.22  0.94
C 5.10  3.03 1.22  1.11
p 0.957 0.888
BATD Z difference between prior to and after treatment,
DSS Z defecation strain score; VAS Z visual analog scale.
Figure 1 Improvement ratios between groups.
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found to be 68% for glycerol trinitrate (GTN) and 8% for
placebo. Similar improvement ratios have been reported in
other studies.2,3 Despite initial efficacy, its long-term re-
sults and effect on disease recurrence are still under dis-
cussion.7 Other organic nitrates that are used in the
treatment of anal fissure include isosorbide dinitrate and
isosorbide mononitrate. Their efficacies have been
observed to be similar to that of GTN.8e10 We also used
isosorbide 5 mononitrate in our study. In 14 (77.8%) of the
18 patients with chronic anal fissure who used the pomade
prepared with 0.2% isosorbide mononitrate, improvement
of anal fissure and significant reduction in pain (no pain in
55.6% and more than 50% reduction in 22.2%) were
observed. While this finding was similar to the findings of
other publications in the literature, it was a little above
average. This might be due to a lack of long-term follow-up
of patients and the small size of the sample.
In this study, where calcium antagonists were adminis-
tered for the first time, sublingual niphedipine was
observed to reduce anal channel rest pressure in healthy
individuals and patients with anal fissure.11 In studies with
topical diltiazem providing improvement in 50% of the GTN
treatment resistance cases is available.4,12e14 This could beFigure 2 Distribution of complication ratios between
groups (%).due to its tolerance being higher than and mechanism of
action being different from those of nitrates.10,11 In our
study, we used 2% diltiazem. Consistent with the findings of
topical diltiazem studies in literature, we observed an
improvement in the fissure and a significant reduction in
pain in 13 (72.2%) of the 18 patients (no pain in 27.8% and
more than 50% reduction in 44.4%).
In a study conducted on internal anal sphincter isolated
from a sheep, the administration of a combination of GTN
and diltiazem was observed to be more efficacious than the
administration of other pharmacological agents as single
agents.15 In our study, we used a mixture consisting of 2%
diltiazem and 0.1% isosorbide 5 mononitrate in Group C;
however, the efficacy of this combination was seen to be
similar to the single agents used in other two groups. In 14
(73.7%) of the 19 patients, improvement in the fissure and a
significant reduction in pain were observed compared to
other two groups (no pain in 42.1% and more than 50%
reduction in 36.8%).
Strain during defecation was also evaluated as an indi-
cator of the patient’s quality of life and time spent in
bathroom. This scoring had only been used in the study by
Takoot and Salaam, where the patients were categorized
into three groups. The first group used GTN, the second
group lidocaine, and the third group a healer cream
(mixture of isosorbide dinitrate, lidocaine, and rutoside). In
all three groups, a reduction in straining after the treat-
ment was observed.16 Our study results were found to be
consistent with those of other studies in the literature. In
all three groups, a significant reduction in straining and
discomfort was observed after treatment compared to
those prior to treatment.
Headache is one of the most important adverse events of
nitrate treatment, and it has been reported to occur in up
to 50% of patients. Headache frequently responds to simple
analgesics. Usually, it is mild and in less than 10% of pa-
tients it necessitates discontinuation of treatment.1e4,8,17
There are publications reporting a positive correlation be-
tween nitrate dose and headache.1,3,18 In this study,
headache ratios for Groups A, B, and C were 22.2%, 5.6%,
and 15.8%, respectively. While it was not statistically sig-
nificant, there were fewer occurrences of headache in the
patient group using diltiazem. A literature search reveals
that nitrates causes significantly fewer or no headaches
compared to diltiazem.2,4,19 The reason why it was statis-
tically not significant might be the low number of study
participants. We aimed to reduce the adverse events
associated with nitrate by combining it with diltiazem and
providing synergistic efficacies similar or superior to those
of a single agent. When patients in Group C were compared
with those in Group A we did not find a statistically
meaningful difference with respect to adverse events and
treatment efficacy. However, in another center, we had a
patient using the pomade consisting of 2% diltiazem and
0.1% isosorbide 5 mononitrate, who was prescribed a
commercially available form containing 0.4% GTN and dis-
continued treatment on the 3rd day due to headache.
Studies with bigger study groups will clearly reveal whether
there is a difference between these agents in terms of
adverse events and treatment efficacy.
In our study, itchiness, however, was recorded as
another important symptom noticed in the 1st week of
Treatment of chronic anal fissure 169treatment. Itchiness ratio observed in Groups A, B, C were
11.1%, 11.1%, and 26.3%, respectively. There were no
statistically significant differences between the three
groups; however, in Group C the itchiness ratio was higher.
In general, these ratios were higher compared to those
reported in literature.20,21 Dermatitis was seen in one
Group B patient. Treatment was halted for 3e4 days. The
patient was applying a dose higher than the dose in
anamnesis and was spreading the medicine to the sur-
rounding tissue. The correct method of use was explained
to the patient and the treatment was continued. Derma-
titis was not seen again. Erectile dysfunction was seen in
one Group C patient. The patient wanted to discontinue
treatment and hence was withdrawn from the study. In
literature, there is no information on erectile dysfunction
as an adverse effect.
A limiting factor of our study could be the lack of a
control group. However, since all patients who were
enrolled in the study had previously been treated unsuc-
cessfully for anal fissure with various treatments, we found
the use of a control group unnecessary.
In conclusion, topical nitrate, topical diltiazem, and
their mixture can be used in the treatment of anal fissure.
With respect to treatment success, none of these is sta-
tistically significantly superior to others.References
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